Bone Abstracts

Objectives: Clinicians practicing in long-term care (LTC) face unique challenges caring for frail elderly individuals including multiple co-morbidities, polypharmacy, and end of life care, and practice guidelines typically do not address this population. Guidance regarding the management of osteoporosis and fracture prevention in LTC, a high-risk population, is needed.Materials and methods: A survey of LTC physicians informed key questions and outcomes, ...

To evaluate the regeneration of alveolar bone after treatment with bone-resorption inhibitors in old acyclic rats that had been through a long period of low estrogen. Thirty-two female Wistar rats with 20 months old intact and ovariectomized (OVX at 4 months of age), were randomized into four groups (n=8/group): i) intact; ii) OVX/O (corn oil); iii) OVX/E2 (17β-estradiol, 400 μg) and iv) OVX/RLX (Raloxifene, 1 mg/kg per day). All treatments began ...

Objectives: Type 2 diabetes mellitus (T2DM) is associated to an higher risk of fractures despite a normal or increased bone mineral density measured by dual-energy X-ray absorptiometry (DXA).The purpose of this 3-years longitudinal study was to assess the changes of quantitative ultrasound (QUS) parameters in a group of postmenopausal women with T2DM and in healthy controls.Materials and method: The analyses were performed on a gro...

Objectives: Osteogenesis imperfecta (OI) is a bone disease mainly caused by collagen type I mutations and characterized by bone fragility. No definitive cure is available and the search for novel treatments is necessary. The small teleost D. rerio is particularly appealing for drug screening approaches. A zebrafish OI model (Chihuahua) carrying in heterozygosis the G574D substitution in the α1 chain of collagen type I is available. To use this model for ...

Introduction: Standard clinical treatments for postmenopausal osteoporosis utilize resorption-inhibiting drugs such as bisphosphonates, which selectively bind to bone mineral but also suppress bone formation over time. Prostaglandin E2 (PGE2) has bone-anabolic effects in vivo, but its clinical utility is hindered by side effects upon systemic administration. Since PGE2 acts on bone via the EP4 receptor, our approach utilizes a specific...

Screening gene function in vivo is a powerful approach to discover novel drug targets in the human genome (Nat Rev Drug Discov 2 38–51, 2003). We present data for 3776 distinct gene knockout (KO) mouse lines with viable adult homozygous mice generated using both gene-trapping and homologous recombination technologies. Bone mass was determined from PIXImus DEXA scans of male and female mice at 14 weeks of age and by microCT analyses of bones from ...

Cadmium (Cd) is regarded as a risk factor for various bone diseases in humans and experimental animals. To compare effects of different routes of Cd administration on femoral bone structure, ten 4-month-old male Wistar rats (group A) were injected intraperitoneally with a single dose of 2 mg CdCl2/kg body weight and killed 36 h after Cd had been injected. Ten 1-month-old male rats (group B) were dosed with a daily Cd intake of 30 mg CdCl2/l in drinking wa...

Objectives: Examine changes in volumetric BMD and cortical structure following Crohn Disease (CD) diagnosis, and identify associations with growth, glucocorticoid exposure and disease activity.Methods: Prospective cohort study in 76 CD participants, ages 5–21 years. Tibia pQCT scans were obtained at diagnosis, 6, 12 and a median of 42 months later. Sex, race and age-specific Z-scores were generated based on >650 controls. Cortical dimen...

Background: Hyperphosphatemic Familial Tumoral Calcinosis (HFTC) and Hyperphosphatemic Hyperostosis Syndrome (HHS) are two phenotypes of a disease associated with autosomal recessive mutations in FGF23, GALNT3 and KL, leading to reduced levels and clinical effects of fibroblast growth factor 23 (FGF23). We describe a consanguineous family with two affected individuals with HFTC and HHS caused by a novel homozygous mutation in GALNT3. We also...

Menopause is accompanied by a decrease in bone mineral density which can be caused by a reduction in bone volume and/or degree of bone matrix mineralization. Both of them are suggested to contribute to the increased fracture risk in postmenopausal individuals. In the present work, we aimed for information whether a drop in bone matrix mineralization is occurring in the perimenopausal stage of women. For this purpose, we measured the bone mineralization density distribution (BM...